Scott Martin
Bristol-Myers Squibb (Germany)(DE)UCB Pharma (United Kingdom)(GB)AstraZeneca (Poland)(PL)Bristol-Myers Squibb (Belgium)(BE)AstraZeneca (United States)(US)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Quinazolinone synthesis and applications, Hepatitis C virus research, Drug-Induced Hepatotoxicity and Protection, Synthesis and biological activity
Most-Cited Works
- → Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)(2013)258 cited
- → Optimising proteolysis-targeting chimeras (PROTACs) for oral drug delivery: a drug metabolism and pharmacokinetics perspective(2020)213 cited
- → Identification of Hepatitis C Virus NS5A Inhibitors(2009)194 cited
- → Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs(2021)131 cited
- → Metabolic Disposition of Osimertinib in Rats, Dogs, and Humans: Insights into a Drug Designed to Bind Covalently to a Cysteine Residue of Epidermal Growth Factor Receptor(2016)128 cited
- → Discovery and Preclinical Characterization of the Cyclopropylindolobenzazepine BMS-791325, A Potent Allosteric Inhibitor of the Hepatitis C Virus NS5B Polymerase